R&D
AstraZeneca’s Tagrisso Combo Extends Survival in Hard-to-Treat Lung Cancer
In the Phase 3 SAFFRON trial, adding Hutchmed’s Orpathys to Tagrisso delayed progression and extended overall survival in EGFR-mutated lung cancer that had developed a MET-driven resistance.